Screener
EBIT at other companies
Other financials
Where this comes from
Calculated from Aquestive Therapeutics, Inc.’s reported figures.
The source filing: Aquestive Therapeutics, Inc.’s 10-Q, filed August 11, 2026. Open the filing →
- Filed
- Aug 11, 2026, 4:10 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001398733-26-000042
FAQ
- What is Aquestive Therapeutics, Inc.'s EBIT?
- Aquestive Therapeutics, Inc. (AQST) reported EBIT of -$8.22M in Q2 2026.
- How has Aquestive Therapeutics, Inc.'s EBIT changed year-over-year?
- Aquestive Therapeutics, Inc.'s EBIT increased by 27.7% year-over-year, from -$11.37M to -$8.22M.
- What is the long-term trend for Aquestive Therapeutics, Inc.'s EBIT?
- Over 4 years (2021 to 2025), Aquestive Therapeutics, Inc.'s EBIT has grown at a 19.6% compound annual growth rate (CAGR), from -$34.68M to -$71.05M.
- What does EBIT mean?
- Earnings before interest and taxes — the profit from the business before financing cost and tax. Uses reported operating income where a company reports it; otherwise pre-tax income plus interest expense. Lets companies be compared on earning power independent of capital structure.
Ask your AI about Aquestive Therapeutics, Inc.'s ebit.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude